These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19089689)

  • 21. Drug delivery to the brain using thermosensitive liposome and local hyperthermia.
    Kakinuma K; Tanaka R; Takahashi H; Sekihara Y; Watanabe M; Kuroki M
    Int J Hyperthermia; 1996; 12(1):157-65. PubMed ID: 8676003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
    Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
    J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
    Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
    J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.
    Nahta R; Hung MC; Esteva FJ
    Cancer Res; 2004 Apr; 64(7):2343-6. PubMed ID: 15059883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
    Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
    Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
    Ito A; Kuga Y; Honda H; Kikkawa H; Horiuchi A; Watanabe Y; Kobayashi T
    Cancer Lett; 2004 Aug; 212(2):167-75. PubMed ID: 15279897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
    Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
    Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
    Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoshell-mediated targeted photothermal therapy of HER2 human breast cancer cells using pulsed and continuous wave lasers: an in vitro study.
    Khosroshahi ME; Hassannejad Z; Firouzi M; Arshi AR
    Lasers Med Sci; 2015 Sep; 30(7):1913-22. PubMed ID: 26137934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation binary targeted therapy for HER-2 positive breast cancers: assumptions, theoretical assessment and future directions.
    Mundy DW; Harb W; Jevremovic T
    Phys Med Biol; 2006 Mar; 51(6):1377-91. PubMed ID: 16510950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery.
    Lee RJ; Wang S; Turk MJ; Low PS
    Biosci Rep; 1998 Apr; 18(2):69-78. PubMed ID: 9743475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and characterization of heat-sensitive immunoliposomes.
    Sullivan SM; Huang L
    Biochim Biophys Acta; 1985 Jan; 812(1):116-26. PubMed ID: 3967009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.
    Al-Batran SE; Ruppert M; Jäger E
    Onkologie; 2011; 34(1-2):42-5. PubMed ID: 21346384
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of a liposomal delivery system for temperature-triggered release of a tumor targeting agent, Ln(III)-DOTA-phenylboronate.
    Djanashvili K; ten Hagen TL; Blangé R; Schipper D; Peters JA; Koning GA
    Bioorg Med Chem; 2011 Feb; 19(3):1123-30. PubMed ID: 20624680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
    Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
    Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene delivery to Her-2+ breast cancer cells using a two-component delivery system to achieve specificity.
    Kullberg M; McCarthy R; Anchordoquy TJ
    Nanomedicine; 2014 Aug; 10(6):1253-62. PubMed ID: 24632244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.